TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03085004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel + Gemcitabine admixture
Description: Following lavage, cysts will be infused with an admixture of 3mg/ml paclitaxel and 19mg/ml gemcitabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Gemcitabine admixture
Description: Following lavage, cysts will be infused with an admixture of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
Study: NCT01773616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT04261101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test-enhanced learning
Description: Test-enhanced learning with short answers of questions regarding diabetes and adrenal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test-enhanced learning
Description: Test-enhanced learning with short answers of questions regarding diabetes and adrenal
Study: NCT04208958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VE800
Description: VE800 is an orally administered (PO) live biotherapeutic product (LBP) consisting of 11 distinct nonpathogenic, nontoxigenic, commensal bacterial strains manufactured under Good Manufacturing Practice (GMP) conditions. These strains were selected for their ability to induce an immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an approved medication that blocks antibodies for certain types of cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Oral Capsule
Description: Vancomycin is an antibiotic used to treat or prevent infection.
Study: NCT03179423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNbAC1
Description: Monthly IV repeated dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Monthly IV repeated dose
Study: NCT04355065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Traning with The Secret Trail of Moon
Description: Patients are pharmacologically stable and receive a cognitive intervention with our videogame once a week in the hospital.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Traning with Therapeutic Chess
Description: This group is pharmacologically stable. This group performs cognitive training through a therapeutic chess protocol designed by a chess psychologist. The training is done from home and we contact them weekly to correct the exercises done and to follow up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: These patients continue their stable pharmacological treatment and do not receive any additional cognitive intervention.~They are contacted weekly by phone to follow up on the group.
Study: NCT01680107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behaviour therapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: cognitive-behaviour therapy
Study: NCT02075307

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry Powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05690490

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection with circumferential incision
Description: The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision will be made around the lesion with an offset of 2-5 mm. Then there will be a one-stage electro excision of the neoplasm using an endoscopic loop.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic submucosal dissection
Description: The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision is made around the lesion. Then dissection will be performed in the submucosal layer.
Study: NCT03311750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/Kg will be administered intravenous over 1 hour on Day 1 every 2 weeks or 9 mg/Kg every 3 weeks.
Study: NCT01909479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023
Description: Individualized once weekly dose of MOD-4023
Study: NCT00682357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and Lidocaine
Description: Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and Lidocaine
Description: Methylprednisolone 16 mg intra-articular and lidocaine 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Lidocaine
Description: Placebo and lidocaine 20 mg
Study: NCT00795548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacitidine
Description: 5-Aza will be administered at doses of 100mg/m2 via subcutaneous injection over a period of 5 days. The total amount per treatment cycle, consisting of 5 days, is 500mg/m². Each treatment cycle is repeated every 28 days, with a treatment pause of 23 days between each 5-Aza cycle, to a total of 6 (optional 8 cycles) cycles.~DLI will be transfused on day +34 with a total count of CD3+ cells of DLI 1-5x10E6CD3+/kg bodyweight. In absence of GvHD DLI transfusion is repeated on day +90 with DLI 1-5x10E7CD3+/kg bodyweight and on day +142 with DLI 1-5x10E8CD3+/kg bodyweight. Additional DLI may be given.
Study: NCT03800342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: see arm/group description
Study: NCT02390674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin
Description: Comparison between ciclosporin and placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT02034175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SomnaPatch
Description: SomnaPatch is a standalone flexible diagnostic skin-adhesive patch with electronics inside. The patch is placed on the patient's face.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polysomnography
Description: Polysomnography performed in a sleep lab is considered a gold standard in diagnosing the sleep breathing disorders.
Study: NCT02093988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical TXA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous TXA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous TXA
Study: NCT01962987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium
Description: Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Description: Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
Study: NCT02937857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment only
Description: standard treatment， such as antiasthmatic,expectorant,antipyretic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment+Xiyanping injection
Description: standard treatment+Xiyanping injection:standard treatment， such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection,0.2-0.4mL/kg/day,qd for 5 days.
Study: NCT03455868

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Sleeve gastrectomy
Study: NCT01801176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI every 3 months during the first year and then every 6 months during the second year and then one MRI up to 36 months
Study: NCT01909479

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once weekly administration of placebo
Study: NCT01773616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyl prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl prednisolone
Study: NCT00631969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil ODT (STAXYN, BAY38-9456)
Description: Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10mg orodispersible tablet (ODT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
Study: NCT01944462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist Pneumococcal Vaccine Program (PPVP)
Description: 1.5 hour educational intervention delivered onsite at collaborating senior center consisting of 3 components: presentation about pneumococcal disease and the vaccine given by a infectious disease-certified pharmacist; 2) skits given by volunteer actors at the senior center to illustrate real world scenarios related to pneumococcal disease and the vaccine; 3) action planning to consist of small group breakouts led by licensed pharmacists and 4) vaccination day which is an optional component following the education program, for participants eligible to receive the vaccine. Vaccination to be provided free of charge to eligible participants who opt to receive it.
Study: NCT03815955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Sedentary Behaviour Modelling
Description: Consistent with social learning theory, the primary care provider and the DIGMA support team will model, demonstrate, and verbalize aspects of increased confidence to perform the 1-hour appointment in a standing position and offer a variety of strategies to cope and overcome any feelings of discomfort. Emphasis will be placed on the strategies the primary care team uses to break sitting with standing and light, incidental movements. It will be anticipated that the participant will observe cues and relevant information specific to their behaviour change and engage in minimal sedentary behaviour.
Study: NCT05327309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Study: NCT01497002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human stem cells
Description: Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (1 course): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8. Allogeneic stem cell transplantation using reduced intensity conditioning: Fludarabine 30 mg/m² day -4 - -2, TBI 200 cGy day 0; GvHD prophylaxis: cyclosporine A and mofetil mycofenolate
Study: NCT02483715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose dual therapy (rabeprazole, amoxicillin)
Description: High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
Description: Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
Study: NCT02994576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab, 1200 mg administered I.V. once
Study: NCT00417235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Sponge (Biopatch TM)
Description: dressing with chlorexidrine sponge versus dressing without chlorexidrine sponge

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Sponge (Biopatch TM)
Description: dressing with chlorexidrine sponge versus dressing without chlorexidrine sponge

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7-day catheter dressing frequency
Description: dressing changes every 7 days versus every classical change every 3 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7-day catheter dressing frequency
Description: dressing changes every 7 days versus every classical change every 3 days
Study: NCT02067104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
Study: NCT02358863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6
Description: Oxaliplatin 85 mg/m2 IV Day 1 every 14 days Leucovorin 400 mg/m2 IV over 2 hours Day 1 5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1
Study: NCT02858531

Intervention type: OTHER
Intervention: data retrieval
Description: data retrieval with the Hospital Information System
Study: NCT03690739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administration according to investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administration according to investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Administration according to investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLD
Description: Administration according to investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administration according to investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLD
Description: Administration 30 mg/m² q21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trabectedin
Description: Administration 1.1 mg/m² q21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administration according to investigator's discretion
Study: NCT01684644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Forest Parenting Programme

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Study: NCT02332772

Intervention type: OTHER
Intervention: Data Collection
Description: Data collected from endoscopy procedures.
Study: NCT03404908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP (transversus abdominis plane block)
Description: the ultrasound-guided regional block of abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375% ropivacaine administered (0.2 mL/kg).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QL (quadratus lumborum block)
Description: the ultrasound-guided regional block of abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with a distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: In both groups (TAP\&QLB) 0.375% ropivacaine will be given (0.2 mL/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: In both groups (TAP\&QLB) 0.375% ropivacaine will be given (0.2 mL/kg)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metamizole
Description: Intravenous metamizole will be used (1.0 gram), up to 4 grams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metamizole
Description: Intravenous metamizole will be used (1.0 gram), up to 4 grams per day
Study: NCT00212030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicorandil
Description: (0∙067 mg/kg as a bolus, followed by 1∙67 μg/kg per min as a 24-h continuous intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Control
Study: NCT03418298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation group
Description: Subjects will performed an internet-based exercise program before surgery
Study: NCT03557151

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care participants will receive the same excellent multidisciplinary Care they would receive at the same center were they not enrolled in the trial. In clinic visits scheduled at approximately 3-month intervals, they will see subspecialty board certified or eligible pediatric endocrinologists, supplemented as needed with involvement of certified diabetes educators, dietitians, social workers or psychologists. HbA1c target is \< 7.5% with no severe hypoglycemia and acceptable quality of life. About half are expected to be on insulin pumps and carbohydrate counting, while the great majority of others are following basal-bolus multiple daily injection regimens, also based on carbohydrate counting. A rising proportion of patients use continuous glucose monitors and this trend is likely to accelerate during the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdisciplinary Care-In Person & Telehealth
Description: TC participants will receive all elements of the Usual Care intervention but they will do so in the context of face to face or telehealth delivery of TC follow-up visits with simultaneous involvement of an advanced practice nurse, dietitian and psychologist at each visit.
Study: NCT01548703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-838
Description: BCI-838 100 mg or matching placebo administered once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-838
Description: BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
Study: NCT02132325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Description: Dignity Therapy/Life Plan will be provided by an advanced practice nurse or chaplain (APN/Chap), who has undergone training in provision of Dignity Therapy (offered through a 3-day group workshop by Dr. Harvey Chochinov).
Study: NCT01914744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: entecavir 0.5 mg/day PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: entecavir 0.5 mg/day PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: lamivudine 100 mg/day PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: lamivudine 100 mg/day PO
Study: NCT00240253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramlintide acetate
Description: Clear, colorless, sterile solution for SC injection
Study: NCT02546557

Intervention type: PROCEDURE
Intervention: Coronary Artery Bypass Graft surgery
Study: NCT00807157

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PROBIOSTICK® during 30 days
Description: Every morning subjects will consume a stick of PROBIOSTICK® during 30 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo during 30 days
Description: Every morning subjects will consume a stick of placebo during 30 days
Study: NCT00376350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: 5 minutes high velocity, low amplitude lumbar thrust

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: 5 minutes high velocity, low amplitude lumbar thrust

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: 5 minutes high velocity, low amplitude lumbar thrust

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Light Massage
Description: light pressure massage of the low back.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light Massage
Description: light pressure massage of the low back.
Study: NCT01548703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-838
Description: BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
Study: NCT01138969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: esomeprazole 20 mg qd for 6 months
Study: NCT01536964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: 2.5mg of morphine will be given post Prasugrel administration with a further 2.5mg 5 minutes later

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 2.5ml of saline will be given post Prasugrel followed by a further 2.5ml as a comparator for the morphine
Study: NCT04813666

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Urinary LAM ELISA:

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urinary LAM ELISA: